Eugene R Ahn

Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

R. Schilsky, F. Meric-Bernstam, M. von Mehren, 2023, JCO precision oncology.